Literature DB >> 21666422

Postinfectious functional gastrointestinal disorders.

Fermín Mearin1.   

Abstract

Functional gastrointestinal disorders are associated with low health-related quality of life and high resource utilization. Postinfectious irritable bowel syndrome (PI-IBS) is a functional gastrointestinal disorder defined as the acute onset of new IBS symptoms in an individual who has not previously met the Rome criteria for IBS, immediately after an acute illness characterized by 2 or more of the following: fever, vomiting, diarrhea, or a positive bacterial stool culture. Although the pathophysiological mechanisms involved in PI-IBS are currently unknown, it is believed that a transitory inflammation leads to subtle but permanent changes in the structure and function of the digestive system that induce symptoms. This review considers recent evidence surrounding the role of inflammatory mediators in the development of hypersensitivity, along with the mediators and mechanisms of abdominal pain and discomfort once the acute inflammation has cleared. Recent data suggest that anatomic changes to mast cells-nerve fibers are necessary, but not sufficient to induce symptoms. It is now possible to estimate the risk of developing PI-FGID based on the presence and relative severity of different risk factors, including prolonged duration of initial illness, toxicity of infecting bacterial strain, smoking, mucosal markers of inflammation, female sex, depression, hypochondriasis, and adverse life events in the preceding 3 months.

Entities:  

Mesh:

Year:  2011        PMID: 21666422     DOI: 10.1097/MCG.0b013e31821fbf58

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

Review 1.  Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman; Jennifer M Colombo; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

2.  Investigation of the effect of military stress on the prevalence of functional bowel disorders.

Authors:  Xian-Zhao Yu; Hai-Feng Liu; Zhen-Xue Sun
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 3.  The microbiota-gut-brain axis in functional gastrointestinal disorders.

Authors:  Giada De Palma; Stephen M Collins; Premysl Bercik
Journal:  Gut Microbes       Date:  2014-06-12

4.  ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.

Authors:  Mark S Riddle; Herbert L DuPont; Bradley A Connor
Journal:  Am J Gastroenterol       Date:  2016-04-12       Impact factor: 10.864

5.  Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial.

Authors:  Wei Huang; Shu-Man Jiang; Lin Jia; Le-Qing You; Yao-Xing Huang; Yan-Mei Gong; Gui-Qin Wang
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

6.  Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.

Authors:  Adam Deising; Ramiro L Gutierrez; Chad K Porter; Mark S Riddle
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-03

Review 7.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

8.  Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness.

Authors:  Chad K Porter; Daniel Choi; Brooks Cash; Mark Pimentel; Joseph Murray; Larissa May; Mark S Riddle
Journal:  BMC Gastroenterol       Date:  2013-03-08       Impact factor: 3.067

9.  Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome.

Authors:  Kurt Hanevik; Einar K Kristoffersen; Steinar Sørnes; Kristine Mørch; Halvor Næss; Ann C Rivenes; Jørn E Bødtker; Trygve Hausken; Nina Langeland
Journal:  BMC Infect Dis       Date:  2012-10-14       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.